XLIFE-SCIENCES-AG
2.11.2020 12:35:12 CET | Business Wire | Press release
Xlife Sciences AG: M.M. Warburg sets price target to EUR 55.75
In their recently published report, the analysts of Deutsche Bankhaus M.M. Warburg set the price target for the shares of the Swiss management company, Xlife Sciences AG (Xetra: XLS) to EUR 55.75. The company's earnings for the financial year 2020 are expected at 10.4 million euros and EBITDA is expected at 10.5 million euros. Due to the high quality portfolio of life science projects, M.M. Warburg sees continued strong earnings growth.
According to the report, the main reasons for the positive valuation are: the high quality of Xlife's 21 projects, the company's lean cost structure and the incredible pipeline of possible future exits. According to Warburg analysts, the share is trading at a significant discount at the current price of around 38 euros due to the recoverability of the project companies. Xlife CEO Oliver R. Baumann is happy about the report. "This confirms that our focus on diversification in the four areas of technology platforms, biotechnology, medical technology and artificial intelligence offers great potential". According to Baumann, an investment at the early stage of a life science project is also highly interesting from a risk perspective as the leverage is greater due to the lower capital investment and the chances for success of a project in the "proof of concept phase" are generally higher.
Strong EBITDA growth until 2022
The management has set ambitious goals for the future. The EBITDA is expected to rise to 67 million euros and the net profit to almost 60 million euros as early as 2022, with an EBITDA margin of 92%. At a strategic level, Xlife intends to make greater use of the synergies between the projects and aims to further increase profitability, with a focus on licensing agreements. In the long term, the company aims to establish itself as a centre of excellence for antibodies, human genetics and personalised medicine and will further diversity its early-stage project portfolio. The long-term dividend yield target is at 3-4%.
About Xlife Sciences AG
Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch
Additional features: M.M. Warburg, Research Publication on Xlife Sciences AG
| Language: | English |
| Company: | Xlife Sciences AG |
| Klausstrasse 19 | |
| 8008 Zürich | |
| Switzerland | |
| Phone: | 0041-44-385-84-60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| WKN: | A2PK6Z |
| Listed: | Regulated Unofficial Market in Frankfurt, Munich |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005456/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
Andersen Consulting indgår en samarbejdsaftale med Ventum Consulting25.3.2026 13:58:00 CET | Pressemeddelelse
Andersen Consulting udvider sin globale platform med tilføjelsen af samarbejdspartneren Ventum Consulting, der er et forretnings- og teknologikonsulenthus med base i Tyskland, der specialiserer sig i digital transformation, enterprise agility, produktudvikling, datadrevet innovation samt nye teknologier såsom AI. Ventum Consulting hjælper organisationer med at bygge bro mellem forretning og teknologi ved at levere skræddersyede løsninger inden for strategi, procesoptimering og implementering af it-løsninger. Virksomhedens ekspertise omfatter data og AI, cybersikkerhed, enterprise architecture, bæredygtighed, cloud-transformation samt agile enablement, hvilket kun er et udsnit af deres omfattende serviceportefølje. Ventum Consulting arbejder med kunder på tværs af brancher, herunder bilindustri og produktion, finansielle tjenester og forsikring, sundhedssektoren og life science-industrien samt den offentlige sektor, for at accelerere digital transformation, styrke driftsmæssig robusthed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom